Journal of Neural Transmission

, Volume 126, Issue 4, pp 449–454 | Cite as

Classical dopamine agonists

  • R. HorowskiEmail author
  • P.-A. Löschmann
Neurology and Preclinical Neurological Studies - Review Article


The pioneering work of Arvid Carlsson has laid the foundation for a number of innovative therapies for severe central nervous system (CNS) diseases. He was awarded the Nobel Price for the discovery of the crucial role of dopamine (DA) as a neurotransmitter in the CNS, thereby forming the basis for the symptomatic therapy of Parkinson’s disease (PD) with l-DOPA and subsequently dopaminergic drugs. Parenteral apomorphine has a short lasting effect in PD, bromocriptine can be administered orally and has a long-lasting effects but is poorly tolerated. Lisuride on the other hand has a high affinity to DA receptors and can be administered orally, parenterally or via the transdermal route of administration. Last but not least Carlsson developed the concepts of presynaptic effects of DA agonists as well as DA partial agonism potentially innovative mechanisms for treatment of PD and schizophrenia.


Apomorphine Bromocriptine Lisuride 



  1. Andén NE, Rubenson A, Fuxe K, Hökfelt T (1967) Evidence for dopamine receptor stimulation by apomorphine. J Pharm Pharmacol 19:627–629CrossRefGoogle Scholar
  2. Birkmayer W, Riederer P (1983) Effects of lisuride on motor function and psychic behaviour. In: Calne DB, Horowski R, McDonald RM, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 453–461Google Scholar
  3. Burstein ES, Carlsson ML, Owens M, Ma JN, Schiffer HH, Carlsson A, Hacksell U (2011) In vitro evidence that (−)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors. J Neural Transm 118:1523–1533CrossRefGoogle Scholar
  4. Calne DB, Teychenne PF, Claveria LF, Eastman R, Greenacre JK, Petrie A (1974) Bromocriptine in Parkinson’s disease. Br Med J 5942:442–444CrossRefGoogle Scholar
  5. Carlsson A (1959) The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 11:490–493Google Scholar
  6. Carlsson A, Lindquist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200CrossRefGoogle Scholar
  7. Carlsson A, Dahlstroem A, Fuxe K, Lindquist M (1962) Histochemical and biochemical detection of monoamine release from brain neurons. Life Sci 4:809–8016CrossRefGoogle Scholar
  8. Chiodini PG, Liuzzi A, Verde G, Cozzi R, Silvestrini F, Marsili MT, Horowski R, Passerini F, Luccarelli G, Borghi PG (1980) Size reduction of a prolactin-secreting adenoma during long-term treatment with the dopamine agonist lisuride. Clin Endocrinol (Oxf) 12:47–51CrossRefGoogle Scholar
  9. Elenkova A, Shabani R, Kalinov K, Zacharieva (2012) Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol 167:17–25CrossRefGoogle Scholar
  10. Ernst AM (1965) Relation between the action of dopamine and apomorphine and their O-methylated derivatives upon the CNS. Psychopharmacologia 21:391–399CrossRefGoogle Scholar
  11. Feser J (1873) Die in neuester Zeit in Anwendung gekommen Arzneimittel; Z Prakt. Veterinärwissenschaft 273, 306, quoted from R. Magnus, 1920Google Scholar
  12. Flückiger E, Wagner HR (1968) 2-Br-alpha-Ergocryptin: Einfluss auf Fertilität und Laktation der Ratte. Experientia 24:1130–1131CrossRefGoogle Scholar
  13. Fuxe K, Corrodi H, Hökfelt T, Lidbrink P, Ungerstedt U (1974) Ergocornine und 2-Br-alpha-ergocryptine: evidence for prolonged dopamine receptor stimulation. Med Biol 52:121–132Google Scholar
  14. Gessa GL (1988) Agonist and antagonist effects of lisuride: electrophysiological evidence. J Neural Transm Suppl 27 201–210. In: Obeso JA, Horowski R, Marsden CD (eds) Continuous dopaminergic stimulation in Parkinson’s disease, Springer Wien, New YorkGoogle Scholar
  15. González-Maeso J, Weisstaub NY, Zhou M, Chan P, Iric L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogen signalling in cortical neurons. Neuron 53:439–452CrossRefGoogle Scholar
  16. Gräf KJ, Neumann F, Horowski R (1976) Effect of the ergot derivative lisuride hydrogen maleate on serum prolactin concentrations in female rats. Endocrinology 98:598–605CrossRefGoogle Scholar
  17. Herzog A, Minne H, Ziegler R (1989) Retroperitoneal fibrosis in a patient with macroprolactinoma treated with bromocriptine. BMJ 298:1315CrossRefGoogle Scholar
  18. Hofmann CH, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B (2006) Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 29:80–86CrossRefGoogle Scholar
  19. Horowski R (1983) Pharmacological effects of lisuride. In: Calne DB, Horowski R, McDonald RM, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 127–139Google Scholar
  20. Horowski R, Wachtel H (1976) Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice. Eur J Pharmacol 36:373–383CrossRefGoogle Scholar
  21. Horowski R, Marsden CD, Obeso JA (1988) Continuous dopaminergic stimulation: state of the art and outlook. J Neural Transm Suppl 27:249–252. In: Obeso JA, Horowski R, Marsden CD (eds) Continuous dopaminergic stimulation in Parkinson’s disease. Springer Wien, New YorkGoogle Scholar
  22. Horowski R, Dorow R, Löschmann P-A, Runge I, Wachtel H, Obeso JA (1989) Oral and parenteral use of lisuride in Parkinson’s disease. In: Przuntek H, Riederer P (eds) Early diagnosis and preventive therapy of Parkinson’s disease. Springer Wien, New York, pp 269–276CrossRefGoogle Scholar
  23. Jackson DM, Jenkins OF, Ross SB (1988) The motor effects of bromocriptine—a review. Psychopharmacology 95:433–446CrossRefGoogle Scholar
  24. Jähnichen S, Horowski R, Pertz HH (2006) Agonism at 5-HT2B receptors is not a class effect of the ergolines. Clin Neuropharmacol 29:80–86CrossRefGoogle Scholar
  25. Jurasz A (1875) Über die Wirkungen des salzsauren Apomorphins Dt. Arch Klin Med 16:41 (quoted from R. Magnus 1920) Google Scholar
  26. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA (1998) Antipsychotic properties of the partial dopamine agonist (−)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry 43:2–11CrossRefGoogle Scholar
  27. Lange KW, Löschmann PA, Wachtel H, Horowski R, Jähnig P, Jenner P, Marsden CD (1992) Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. Eur J Pharmacol 212:247–252CrossRefGoogle Scholar
  28. Liuzzi A, Chiodini PG, Oppizzi G, Botalla L, Verde G, De Stefano L, Colussi G, Gräf KJ, Horowski R (1978) Lisuride hydrogen maleate: evidence for a long-lasting dopaminergic activity in humans. J Clin Endocrinol Metab 46:196–202CrossRefGoogle Scholar
  29. Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G (1985) Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 313:656–659CrossRefGoogle Scholar
  30. Löschmann PA, Horowski R, Wachtel H. Bromerguride - an ergoline derivative with atypical neuroleptic properties. Clin Neuropharmacol (1992)15(Suppl 1 Pt A):263A–264ACrossRefGoogle Scholar
  31. Luquin MR, Obeso JA, Martínez-Lage JM, Tresguerres J, Parada J, Nieuweboer B, Dorow R, Horowski R (1987) Parenteral administration of lisuride in Parkinson’s disease. Adv Neurol 45:561–568Google Scholar
  32. MacLeod RM, Lehmeyer JE (1974) Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. Endocrinology 94:1077–1085Google Scholar
  33. Matthiesen A, Wright CRA (1869) Proc R Soc 17:455–460 (quoted from R. Magnus 1920) CrossRefGoogle Scholar
  34. McDonald RJ, Horowski R (1983) Lisuride in the treatment of parkinsonism. Parenteral administration of lisuride in Parkinson’s disease. Eur Neurol 22:240–255CrossRefGoogle Scholar
  35. Pieri L, Keller HH, Burkard W, da Prada M (1978) Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis. Nature 272:278–279CrossRefGoogle Scholar
  36. Rehse K (1978) Neuropsychotrope Aktivität und Toxizität von Oxidationsprodukten des Apomorphin. Arch Pharm 311:360–363CrossRefGoogle Scholar
  37. Seemann D, Danielczyk W, Ogris E, Jellinger K, Riederer P (1984) Dopaminergic agonists—effects on multiple receptor sites in Parkinson’s disease. In: Callaghan N, Galvin R (eds) Recent research in neurology. Pitman, Chichester, pp 49–60Google Scholar
  38. Stocchi F (2008) Use of apomorphine in Parkinson’s disease. J Neurol Sci 29(Suppl 5):383–386. CrossRefGoogle Scholar
  39. Stocchi F, Ruggieri S, Antonini A, Baronti F, Brughitta G, Bellantuono P, Bravi D, Agnoli A (1988) Subcutaneous lisuride infusion in Parkinson’s disease: clinical results using different modes of administration. J Neural Transm Suppl 27:27–33Google Scholar
  40. Stocchi F, Ruggieri S, Vacca L, Olanow CW (2002) Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease. Brain 125:2058–2066CrossRefGoogle Scholar
  41. Struppler A, Von Uexkull T (1953) Untersuchungen zum Wirkungsmechanismus von Apomorphin auf den Parkinson-Tremor. Z Klin Med 152:46–57Google Scholar
  42. Svensson K, Eriksson E, Carlsson A (1993) Partial dopamine receptor agonists reverse behavioral, biochemical and neuroendocrine effects of neuroleptics in the rat: potential treatment of extrapyramidal side effects. Neuropharmacology 32:1037–1045CrossRefGoogle Scholar
  43. Weil C (1986) The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review. Curr Med Res Opin 10:172–195CrossRefGoogle Scholar
  44. Woitalla D, Müller T, Benz S, Horowski R, Przuntek H (2004) Transdermal lisuride delivery in the treatment of Parkinson’s disease. J Neural Transm Suppl 68:89–95Google Scholar
  45. Wuttke W, Cassell E, Meites J (1971) Effects of ergocornine on serum prolactin and LH, and on hypothalamic content of PIF and LRF. Endocrinology 88:737–741CrossRefGoogle Scholar
  46. Zikán V, Semonský M (1960) Mutterkornalkaloide XVI. Einige N-(d-6-methylisoergolenyl-8)-, N-(d-6-methylergolenyl-8)- und N-(d-6-methylergolin(I)-yl-8)-N′-substituierte Harnstoffe. Collect Czech Chem Commun 25:1922–1928CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Antaxios GmbHWildenbruchGermany
  2. 2.Pfizer Pharma GmbHBerlinGermany

Personalised recommendations